122 related articles for article (PubMed ID: 10170453)
21. A pharmacoeconomic evaluation of major depressive disorder (Italy).
Casciano J; Arikian S; Tarride JE; Doyle JJ; Casciano R
Epidemiol Psichiatr Soc; 1999; 8(3):220-31. PubMed ID: 10638040
[TBL] [Abstract][Full Text] [Related]
22. The prospective, 24-week assessment of cost-efficacy of and compliance to antidepressant medications in a rural setting (PACECAR) study.
Rao TSS; Manohar JS; Raman R; Darshan MS; Tandon A; Karthik KN; Saraswathi N; Das K; Harsha GT; Kunkeri SP; Andrade C
Indian J Psychiatry; 2017; 59(2):157-163. PubMed ID: 28827861
[TBL] [Abstract][Full Text] [Related]
23. A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal.
Silva Miguel L; Silva Miguel N; Inês M
Cost Eff Resour Alloc; 2013 Apr; 11(1):8. PubMed ID: 23587174
[TBL] [Abstract][Full Text] [Related]
24. Do productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders.
Krol M; Papenburg J; Koopmanschap M; Brouwer W
Pharmacoeconomics; 2011 Jul; 29(7):601-19. PubMed ID: 21545189
[TBL] [Abstract][Full Text] [Related]
25. Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy.
Lieberman DZ; Massey SH
Core Evid; 2010 Jun; 4():67-82. PubMed ID: 20694066
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective.
Vera-Llonch M; Dukes E; Rejas J; Sofrygin O; Mychaskiw M; Oster G
Eur J Health Econ; 2010 Feb; 11(1):35-44. PubMed ID: 19506926
[TBL] [Abstract][Full Text] [Related]
27. The economic impact of introducing serotonin-noradrenaline reuptake inhibitors into the Brazilian national drug formulary: cost-effectiveness and budget-impact analyses.
Machado M; Iskedjian M; Ruiz IA; Einarson TR
Pharmacoeconomics; 2007; 25(11):979-90. PubMed ID: 17960955
[TBL] [Abstract][Full Text] [Related]
28. Pharmacoeconomic evaluation of antidepressants : a critical appraisal of methods.
Iqbal SU; Prashker M
Pharmacoeconomics; 2005; 23(6):595-606. PubMed ID: 15960555
[TBL] [Abstract][Full Text] [Related]
29. Economic considerations in the prescribing of third-generation antidepressants.
Montgomery S; Doyle JJ; Stern L; McBurney CR
Pharmacoeconomics; 2005; 23(5):477-91. PubMed ID: 15896099
[TBL] [Abstract][Full Text] [Related]
30. The cost effectiveness of tapered versus abrupt discontinuation of oral cyclosporin microemulsion for the treatment of psoriasis.
Hakkaart-van Roijen L; Verboom P; Redekop WK; Touw KR; Rutten FF
Pharmacoeconomics; 2001; 19(5 Pt 2):599-608. PubMed ID: 11465304
[TBL] [Abstract][Full Text] [Related]
31. The economics of selective serotonin reuptake inhibitors in depression: a critical review.
Frank L; Revicki DA; Sorensen SV; Shih YC
CNS Drugs; 2001 Jan; 15(1):59-83. PubMed ID: 11465013
[TBL] [Abstract][Full Text] [Related]
32. The need for an iterative process for assessing economic outcomes associated with SSRIs.
Skaer TL; Sclar DA; Robison LM; Galin RS
Pharmacoeconomics; 2000 Sep; 18(3):205-14. PubMed ID: 11147388
[TBL] [Abstract][Full Text] [Related]
33. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom.
Freeman H; Arikian S; Lenox-Smith A
Pharmacoeconomics; 2000 Aug; 18(2):143-8. PubMed ID: 11067648
[TBL] [Abstract][Full Text] [Related]
34. A critical review of published economic modelling studies in depression.
Jones MT; Cockrum PC
Pharmacoeconomics; 2000 Jun; 17(6):555-83. PubMed ID: 10977394
[TBL] [Abstract][Full Text] [Related]
35. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.
Griffiths RI; Sullivan EM; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
Pharmacoeconomics; 1999 May; 15(5):495-505. PubMed ID: 10537966
[TBL] [Abstract][Full Text] [Related]
36. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder.
Einarson TR; Addis A; Iskedjian M
Pharmacoeconomics; 1997 Aug; 12(2 Pt 2):286-96. PubMed ID: 10170453
[TBL] [Abstract][Full Text] [Related]
37. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
[TBL] [Abstract][Full Text] [Related]
38. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials.
Einarson TR; Arikian SR; Casciano J; Doyle JJ
Clin Ther; 1999 Feb; 21(2):296-308. PubMed ID: 10211533
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Guaiana G; Meader N; Barbui C; Davies SJ; Furukawa TA; Imai H; Dias S; Caldwell DM; Koesters M; Tajika A; Bighelli I; Pompoli A; Cipriani A; Dawson S; Robertson L
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD012729. PubMed ID: 38014714
[TBL] [Abstract][Full Text] [Related]
40. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
